BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8427970)

  • 1. Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells.
    Lemoli RM; Igarashi T; Knizewski M; Acaba L; Richter A; Jain A; Mitchell D; Levy J; Gulati SC
    Blood; 1993 Feb; 81(3):793-800. PubMed ID: 8427970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy.
    Gulati SC; Lemoli RM; Igarashi T; Atzpodien J
    Leuk Lymphoma; 1994 Feb; 12(5-6):427-33. PubMed ID: 8180606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photoradiation methods for purging autologous bone marrow grafts.
    Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
    Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts.
    Atzpodien J; Gulati SC; Strife A; Clarkson BD
    Blood; 1987 Aug; 70(2):484-9. PubMed ID: 2955818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
    Lemoli RM; Gulati SC
    Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merocyanine 540 mediated photolysis of normal bone marrow, committed hemopoietic progenitors and neoplastic cells. implications for bone marrow purging.
    Lydaki E; Dimitriou H; Papazoglou T; Liu WQ; Kalmanti M
    Leuk Res; 1997 Jul; 21(7):641-50. PubMed ID: 9301685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro.
    Glück S; Chadderton A; Ho AD
    Photochem Photobiol; 1996 Jun; 63(6):846-53. PubMed ID: 8992505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of clonogenic tumor cells from HL-60, Daudi, and U-937 cell lines by laser photoradiation therapy: implications for autologous bone marrow purging.
    Gulliya KS; Pervaiz S
    Blood; 1989 Mar; 73(4):1059-65. PubMed ID: 2920207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
    Stiff PJ; Schulz WC; Bishop M; Marks L
    Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of benzoporphyrin derivative, a photosensitizer, in selective destruction of leukemia cells using a murine tumor model.
    Jamieson C; Richter A; Levy JG
    Exp Hematol; 1993 May; 21(5):629-34. PubMed ID: 8513863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow.
    Atzpodien J; Gulati SC; Clarkson BD
    Cancer Res; 1986 Oct; 46(10):4892-5. PubMed ID: 3756850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
    Gidáli J; Fehér I; Kovács P
    Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of photodynamic therapy in bone marrow purging.
    Mulroney CM; Glück S; Ho AD
    Semin Oncol; 1994 Dec; 21(6 Suppl 15):24-7. PubMed ID: 7992104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
    Wiley JM; Yeager AM
    Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
    Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
    Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors.
    Larocca LM; Teofili L; Leone G; Sica S; Pierelli L; Menichella G; Scambia G; Benedetti Panici P; Ricci R; Piantelli M
    Br J Haematol; 1991 Dec; 79(4):562-6. PubMed ID: 1772777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.